Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Clinico-Radiological-Pathologic Profile and Outcomes of Lung Transplant in Post–COVID-19 Phenotype: A Single Center Experience

Unmil Shah\(^{a,}\)\(^{a}\), Vijil Rahulana\(^{a}\), Srinivas Ravipatia\(^{b}\), Sharanya Kumar\(^{b}\), Anoop Mohandas Kamath\(^{b}\), Santosh Korib\(^{a}\), Sushant Pandab\(^{a}\), Vivek Singha\(^{a}\), Pradeep Kumr\(^{a}\), Prasanna Gopalam\(^{b}\), I. Satish Raoc\(^{c}\), Abhiram Kalle\(^{c}\), Manish Dass\(^{d}\), Prem Anand John\(^{d}\), Mahesh Bangalore Nagaraj\(^{d}\), Prabhat Dutta\(^{b}\), and Sandeep Attaward\(^{d}\)

\(^{a}\)Department of Transplant Pulmonology, Krishna Institute of Medical Sciences, Secunderabad, India; \(^{b}\)Department of Transplant Anesthesiology and Critical Care, Krishna Institute of Medical Sciences, Secunderabad, India; \(^{c}\)Department of Pathology, Krishna Institute of Medical Sciences, Secunderabad, India; and \(^{d}\)Department of Transplant Cardio-Thoracic Surgery, Krishna Institute of Medical Sciences, Secunderabad, India

ABSTRACT

Background. Lung transplantation (LTx) has come as hope for select patients with post-COVID acute respiratory distress syndrome (ARDS). It has a different phenotype with unique challenges. We aimed to bring out our experience with and outcomes of LTx for post-COVID ARDS.

Methods. This study is retrospective case series from a single center in India. All the patients with post-COVID end stage lung disease (ESLD) who underwent bilateral LTx between 1st May 2020 and 30th August 2021 were included. LTx was performed following no improvement with optimal medical management with adequate time provided for recovery. Information relating to demographics, comorbidities, pretransplant status, perioperative parameters, gross and histopathological findings of explanted lungs, posttransplant morbidity, and mortality were analyzed.

Results. This study included 23 patients. The median age of the patients in this study was 42 years and 20 participants were men (87%). The mean duration of intensive care unit stay was 15.83 ± 6.61 days. Mortality was observed among 8 participants (34.78%). Mean survival time was 34.54 weeks. Among the 8 patients who expired, the cause of death was sepsis for 6 patients (75.0%), neurologic cerebrovascular accident for 1 patient (12.5%), and cytomegalovirus for 1 patient (12.5%). All the deaths were reported in primary graft dysfunction grade 2 & 3 category. No rejections were observed on first and third month surveillance biopsies.

Conclusions. LTx is the definitive option for survival in select patients with severe post–COVID-19–associated ESLD. This study brings out various challenges involved in such phenotypes and also observations in postoperative recovery.

As per the World Health Organization, as of January 2022, India has had 35,875,790 confirmed COVID-19 cases, including 484,213 mortalities [1]. Worldwide, there have been 308,458,509 confirmed cases of COVID-19, including 5,492,595 deaths [1]. Current evidence suggests acute respiratory distress syndrome (ARDS) is the most common pulmonary complication of the COVID-19 [2]. Various mechanisms of lung injury in COVID-19 have been described, with both viral and immune-mediated mechanisms being implicated [3]. A smaller percentage of patients with more severe disease require ventilatory support and are admitted to high dependency and intensive care units (ICUs). In a Chinese study of 1099 hospitalized COVID-19 patients, the use of mechanical ventilation, death, or admission to an ICU occurred in 67 patients (6.1%), including 5.0% who were admitted to the ICU, 2.3% who underwent invasive mechanical ventilation, and 1.4% who

*Address correspondence to Unmil Shah, MD. Department of Transplant Pulmonology, Heart and Lung Transplant Institute, Krishna Institute of Medical Sciences, Minister Road, Krishna Nagar Colony, Begumpet, Secunderabad, Telangana 500003. E-mail: drunmilshah@gmail.com

0041-1345/20
https://doi.org/10.1016/j.transproceed.2022.03.007

Transplantation Proceedings, 54, 1494–1503 (2022)

1494
died. Extracorporeal membrane oxygenation (ECMO) was performed in 5 patients with severe disease (0.5%) [4]. The mortality associated with COVID-19 is considerable—in a large UK study by Vlachos et al, 18% of them were admitted to the ICU, 52% met criteria for ICU outreach team activation, and 61% had treatment limitations placed during their admission. Hospital mortality was 26% and ICU mortality was 34% [5], concluding that COVID-19 is associated with a high burden of mortality for patients treated in the ward and the ICU hospital mortality was independently associated with increasing age, male sex, history of chronic kidney disease, increasing baseline C-reactive protein level, and dyspnea at presentation. In a review by George et al, COVID-19-related ICU mortality has been reported to be between 16% and 78% [6]. Lung transplantation (LTx) has been offered as a life-saving therapy for select patients with COVID-19 who have persistent respiratory failure despite several weeks or months of support in the ICU. Most patients who progress to severe respiratory failure do have comorbidities that may be a challenge in deciding transplant candidacy. Many will develop secondary complications such as renal dysfunction, muscle wasting, or other organ failure while on ECMO as mentioned by Cypel and Keshavjee [7]. LTx can be considered as a salvage therapy for carefully selected patients who have severe treatment-refractory ARDS as described by Lang et al [8].

So far most of the published studies are based on anecdotal case reports and small sample size case series. To understand the outcomes and factors associated with the outcomes is challenging owing to such small sample size. The experiences of other centers with higher volumes of data may throw light on these aspects, if not providing scientifically robust inferences. These studies may establish a strong platform and provide meaningful insights for further large scale and scientifically robust studies.

Here we report a retrospective study, a single center experience of 23 LTx done in recipients with post-COVID fibrotic progressive end stage lung disease (ESLD). We also describe challenges faced preoperatively as well as postoperatively for such recipients. This is presumably the first case series from a single center in India describing LTx experience in such phenotypes with reasonable outcomes.

**METHODS AND MATERIALS**

Patients received treatment according to the local standard of care from a multidisciplinary COVID-19 care team. Referral to the LTx team was made when at least 4 weeks has elapsed since the onset of respiratory failure and there was no evidence of lung recovery as agreed by the multidisciplinary team as per criteria elaborated by the Toronto group [7]. Not all patients with severe COVID-19 who were treated at the respective centers were referred to LTx after 4 weeks. Common reasons that precluded LTx evaluation included multiorgan failure, inability to assess neurologic status if the patient was unresponsive or not awake, complications such as sepsis or stroke, and general contraindications relevant to LTx. Each patient was then evaluated by the LTx team with standard evaluation protocol and considered a candidate for transplant if other programmatic criteria were met, according to the International Society for Heart and Lung Transplantation guidelines. Patients with multiorgan failure were excluded from LTx evaluation for COVID-19. All patients underwent extensive pulmonary rehabilitation for optimization while on waitlist. All recipients were operated with conventional clamshell incision. All recipients were transplanted on converting venovenous (VV) to venoarterial (VA) ECMO intraoperatively. Intraoperatively, all patients received induction immunosuppression with Inj Basiliximab (20 mg) along with Inj Methylprednisolone (1000 mg IV). Postoperatively, depending on PaO2/FiO2 ratios, hemodynamics, lung compliance, radiological findings, and cardiac function, ECMO weaning was initiated. All recipients postoperatively were started on a 3-drug immunosuppression regimen of steroids, tacrolimus, and mycophenolate mofetil. Routine surveillance bronchoscopies were performed regularly to monitor anastomotic healing, collect broncho-alveolar lavages if required, and so on. All recipients postoperatively underwent pulmonary rehabilitation, early mobilization, and judicious nutritional support.

LTx performed between May 2020 and August 2021 in patients with post-COVID fibrotic progressive ESLD (post-ARDS) were taken into consideration. We collected data relating to patient demographics, comorbidities, pretransplant status (clinical, radiological, medical course, and indications for LTx), perioperative parameters, gross and histopathological findings of explanted lungs, posttransplant morbidity, and mortality. Chest computed tomography was done for all patients preoperatively showing common radiological signs of consolidations, reticular changes, interstitial fibrosis, and patchy ground glass opacities. (Fig 1). This study received approval from an internal ethics committee in compliance with the ethical standards set forth in the Helsinki Congress (Approval no: KIM S/ECB MHW 202 I/26.03).

**RESULTS**

Characteristics of Study Population

A total of 23 bilateral LTx in such phenotypes were performed between May 2020 and August 2021. All of them were transferred from tertiary care hospitals across India to our Transplant Hospital. All of them were endotracheal reverse transcription-polymerase chain reaction—negative for SARS-CoV-2 infection for 2 samples taken at least 24 to 48 hours apart preoperatively. The median age of patients in this study was 42 years, with 3 people aged 60 years or above (13%) (Table 1). Twenty were men (87%). Five subjects had normal body mass index (21.7%), 13 were overweight 13 (56.5%), and 5 were obese (21.7%). Out of 23 recipients, 8 recipients were B positive (34.7%), 5 were A positive (21.7%), 9 were O positive (39.1%), and 1 was AB positive (4.3%). All 23 recipients received Remdesivir, steroids, and anticoagulants as part of their COVID treatment. Among the study population, Hypertension was the most common morbidity among 7 (30.4%), followed by diabetes among 3 (13%) and coronary artery disease among 2 (8.7%) participants. The mean ventilation and ECMO days were 48.87 ± 23.43 and 43.78 ± 24.25 respectively (Table 2).

Out of 23 recipients, 22 patients were supported with VV ECMO (conventional dual cannulae fem-iijv). All 22 patients were awake while on ECMO. One patient had ESLD post-COVID leading to respiratory failure requiring high flow nasal cannula with 40 lit flow.
Preoperative and Intraoperative Parameters

The mean ischemia time on right and left sides were 356 ± 78.58 and 232.35 ± 81.23 minutes respectively. All recipients required multiple blood product transfusions intraoperatively; the median number of blood products used were (11 (10,13)). The median number of cryo, FFP, leukocyte depleted packed red blood cells and random donor platelets were (2 (1,2), 4 (2,4), 3 (2,4), and 3.5 (2,4)) respectively (Table 2).

Postoperative Parameters

At 72 hours posttransplant, 4 (17.4%) participants each had primary graft dysfunction (PGD) grade 0 and grade 1, 7 had grade 2 (30.4%), and 8 had grade 3 PGD (34.8%) (Table 3). The mean duration of ICU stay was 15.83 ± 6.61 days, and the mean hospital stay duration was 62.74 ± 32.42 days. Posttransplant morbidity included acute kidney injury requiring Renal Replacement Therapy in 6 recipient (26%), critical illness neuropathy or neuromuscular weakness in 13 recipients (56.5%),
and airway anastomotic stenosis requiring balloon dilatation in 8 recipients (34%) with SEMS-covered stenting done subsequently in 5 recipients (21%) (Fig 2). Five recipients (21%) were discharged with tracheostomy while the rest were successfully decannulated in wards. All recipients were mobilizing well at time of discharge.

Pathology of COVID-19 Lungs

Pathologic correlation: macroscopic. The following macroscopic features were commonly noted: external surface pleura showing, in Fig 3A patchy fibrotic areas and irregular nodularity, cut surfaces showing patchy subpleural nodules were observed; in Fig 3B, cystic changes and few dilated thick-walled bronchi were observed; in Fig 3C shrunken fibrotic lungs were observed; and in Fig 3D a lung with a cavity was observed (the weight of explanted lungs ranged from 210-895 g).

Pathologic correlation: histopathological. The following various histopathological findings were noted (Fig. 4):

a. Nonspecific interstitial pneumonia-like changes with focal spatial heterogeneity;
b. Focal areas of usual interstitial pneumonia-like changes, areas of interstitial fibrosis with chronic inflammation and hemorrhage;
c. Alveolar spaces and bronchial lumen showing luminal neutrophilic abscess;
d. Diffuse alveolar damage with hyaline membrane formation;
e. Vessels showing luminal narrowing with medial hypertrophy, vessels showing thrombi in lumen;
f. Focal areas showing temporal heterogeneity and microthrombosing, prominent perivascular edema with stromal fibroblastic proliferation;
g. Focal areas of peribroncholar fibrosis and areas of mucosal ulceration, sections from cystic areas showing dilated bronchioles with denudated or sloughed off epithelium, interstitial spaces with diffuse lymphomononuclear infiltrates;

### Table 2. Summary of Preoperative and Intraoperative Parameters (N = 23)

| Parameter                        | Summary                        |
|----------------------------------|--------------------------------|
| **Baseline Parameters**          |                                |
| Pretreatment ventilation (d)     | 48.87 ± 23.43 (0, 90)          |
| Pretreatment total ECMO (d)      | 43.78 ± 24.25 (0, 93)          |
| **Total ECMO days (wk) (%)**     |                                |
| <6 weeks                         | 12 (52.2)                      |
| ≥6 weeks                         | 11 (47.8)                      |
| **Characteristics of explant**   |                                |
| Left explant volume (mm³)        | 1051.09 ± 444.08 (157.50, 2058) |
| Right explant volume (mm³)       | 1461.29 ± 534.67 (726, 2700)   |
| Left explant lung weight (g)     | 462.52 ± 137.54 (213, 684)     |
| Right explant lung weight (g)    | 539.09 ± 154.9 (210, 895)      |
| Ischemia time left (min)         | 356 ± 78.58 (200, 512)         |
| Ischemia time right (min)        | 232.35 ± 81.23 (94, 381)       |
| **Intraop total no. of blood products (Median [IQR])** | 11 (10, 13) |
| Intraop cryo (no. of units)      | 2 (1, 2)                       |
| Intraop FFP (no. of units)       | 4 (2, 4)                       |
| Intraop LDP/RBC (no. of units)   | 3 (2, 4)                       |
| Intraop RDP (no. of units)       | 3.5 (2, 4)                     |

*ECMO*, extracorporeal membrane oxygenation; *FFP*, fresh frozen plasma; *IQR*, interquartile range; *intraop*, intraoperative; *LDP/RBC*, leukocyte depleted packed red blood cells; *preop*, preoperative; *RDP*, random donor platelets.

### Table 3. Summary of Postoperative Parameters (N = 23)

| Parameter                        | Summary                        |
|----------------------------------|--------------------------------|
| **PGD grade at 72 h (%)**        |                                |
| 0                                | 4 (17.4)                       |
| 1                                | 4 (17.4)                       |
| 2                                | 7 (30.4)                       |
| 3                                | 8 (34.8)                       |
| **Post-LTx parameters**          |                                |
| No. of days in ICU               | 15.83 ± 6.61 (6, 28)           |
| Hospital stays (d)               | 62.74 ± 32.42 (16, 150)        |
| Post LTx duration of follow up   | 4 (3.9)                        |
| (mo; Median [IQR])               |                                |
| **Status at final follow-up (%)**|                                |
| Alive                            | 15 (65.2)                      |
| Expired                          | 8 (34.78)                      |
| **Cause of death (n = 8) (%)**   |                                |
| Sepsis                           | 6 (75.0)                       |
| Neurologic CVA                   | 1 (12.5)                       |
| CMV                              | 1 (12.5)                       |

*CMV*, cytomegalovirus; *CVA*, cerebrovascular accident; *ICU*, intensive care unit; *LTX*, lung transplantation; *PGD*, primary graft dysfunction.

**Fig. 2.** Airway complications. (A) Left anastomotic stenosis. (B) Right mainstem bronchial SEMS-covered stent.
h. Residual alveolar lumina showing neutrophilic abscess, foamy histiocytic collection, with focal macrophage proliferation, prominent squamous metaplasia;

i. Type 2 pneumocyte hyperplasia, patchy areas of organizing pneumonia, myogenic metaplasia with fibroblastic foci, some sections showing honeycombing with denudation of lining epithelium, lymph nodes showing reactive hyperplasia;

j. One of the explanted lungs showing infarcted areas with large colonies of fungi with narrow septate, branching hyphal forms with parallel walls showing both tissue- and angio-invasion (highlighted on Gomori's Methenamine Silver stain) proving to be Aspergillus species;

k. One of the explanted lungs also showing scattered necrotizing granulomas warranting antituberculosis treatment posttransplant.

Survival and Cause of Mortality
The median post-LT duration of follow-up was 4 (3, 9) months. Out of 23, 15 participants were alive (65.22%) and 8 participants were dead (34.78%). Among the 8 patients who expired, the cause of death was sepsis for 6 patients (75.0%), neurologic cerebrovascular accident for 1 patient (12.5%), and cytomegalovirus for 1 patient (12.5%) (Table 3). Among the 6 sepsis deaths, 2 were related to the Klebsiella pneumoniae multidrug resistant organism, carbapenem-resistant strains, and multigang dysfunction, 1 recipient had vancomycin-resistant enterococci sepsis, and 3 recipients had fungal sepsis (non-Albicans candida). We didn’t see any episodes of acute cellular rejection or antibody-mediated rejection posttransplant in 1- and 3-month surveillance biopsies.

Kaplan-Meier Survival Analysis (in Weeks)
The mean survival time for the patients was 34.540 weeks. The median survival time for the patients was 20 weeks (ie, 50% of the survival was achieved in 20 weeks [Fig 5]).

Factors associated with mortality
Mortality was higher among patients aged 60 and above compared with patients <60 years of age (66.67% vs 30%, \( P \approx .27 \)). Patients with any comorbidity had a higher proportion of mortality (50% vs 26.67%, \( P \approx .37 \)). Patients with preoperative ECMO days of 6 weeks or more also had higher mortality (45.5% vs 25%, \( P \approx .30 \)). Even among patients with preoperative ECMO of more than 6 weeks, 54.5% survived. The median number of preoperative ventilation days, ECMO days, and the number of intraoperative blood products was higher among patients who died. All of the deaths were reported in the PGD grade 2 & 3 category, with no deaths within the PGD 0 & 1 category. The median postoperative hospital days were lower in the mortality group, suggesting intrahospital mortality (Table 4).

Among the recipients, 14 had positive blood cultures (60.86%). One recipient showed Pseudomonas, 3 had K pneumoniae, 2 had Enterococcus, 1 had Enterobacter, 1 showed Stenotrophomonas maltophilia, 1 showed Elizabeth kingiae, 1 showed Chryseobacterium, and 4 showed Candida auris.

DISCUSSION
We performed 23 bilateral LTxs in recipients affected with post-COVID fibrotic progressive ESLD. We treated the patients who underwent LTxs for COVID-19 with a typical three-drug
immunosuppression regimen including calcineurin inhibitors, an anti-metabolite, and steroids. They were also administered solumedrol and basiliximab before reperfusion as part of our induction immunosuppression protocol for all patients undergoing LTx. In addition, they received antimicrobial drugs directed toward the pathogens isolated from the native lungs before transplant. All recipients underwent serial bronchoscopies to monitor anastomotic healing, to collect broncho-alveolar lavages to monitor or rule out infections, and for toileting. There was no recurrence of SARS-CoV-2 infection in allografts.

We faced certain challenges preoperatively as well as postoperatively.

The preoperative challenges were: 1. recipients were referred to the transplant center after prolonged ICU stays on mechanical ventilation, 2. pre-existing sepsis and infections and their control before LTx, 3. significant neuro-muscular weakness or critical illness neuropathy affecting both upper and lower limbs, 4. prolonged ECMO runs initiated as bridge to transplant, 5. pulmonary rehabilitation limitations on ECMO, and 6. maintaining adequate and prolonged nutritional support.
Table 4. Comparison of Demographic variables between status at final follow up (N = 23)

| Demographic Variables | Alive | Expired | $\chi^2$/Fisher Exact | P value |
|-----------------------|-------|---------|------------------------|---------|
| **Age group (%)**     |       |         |                        |         |
| <60 (n = 20)          | 14 (70)| 6 (30)  | 1.54                   | .27     |
| ≥60 (n = 3)           | 1 (33.33)| 2 (66.67)|                      |         |
| **Sex (%)**           |       |         |                        |         |
| Male (n = 20)         | 13 (65)| 7 (35)  | 0.003                  | 1.00    |
| Female (n = 3)        | 2 (66.67)| 1 (33.33)|                      |         |
| **Body mass index (%)**|      |         |                        |         |
| Normal (n = 5)        | 3 (60) | 2 (40)  | 0.619                  | .73     |
| Overweight (n = 13)   | 8 (61.5)| 5 (38.5)|                      |         |
| Obese (n = 5)         | 4 (80)| 1 (20)  |                        |         |
| **Comorbidities**     |       |         |                        |         |
| Yes (n = 8)           | 4 (50) | 4 (50)  | 1.252                  | .37     |
| No (n = 15)           | 11 (73.33)| 4 (26.67)|                      |         |
| **Pretreatment ventilation d**| 52 (33.56)| 47.5 (30.25,79)|                      | .77     |
| **Total ECMO d**      | 37 (26.52)| 53.5 (19.75,76.25)|                      | .60     |
| **Total ECMO wk**     | 5.29 (3.71, 7.43)| 7.64 (2.82, 10.89)|                      | .60     |
| **Total ECMO (wk)**   |       |         |                        |         |
| <6 wk (n = 12)        | 9 (75.0)| 3 (25)  | 1.059                  | .30     |
| ≥6 wk (n = 11)        | 6 (54.5)| 5 (45.5)|                      |         |
| **Explant lung weight left (g)**| 460 (353,386)| 499.5 (345.75,587.5)|                      | .65     |
| **Explant lung weight right (g)**| 541 (380,644)| 590 (507.5,688)|                      | .22     |
| **Volume (explant dimension-left)**| 1017.5 (825, 1275)| 1079 (838.75, 1225.5)|                      | .74     |
| **Volume (explant dimension-right)**| 1309 (897.75, 1584)| 1606 (1158.75, 2089.05)|                      | .16     |
| **Ischemia time left (min)**| 351 (300,410)| 349 (275.25,425.5)|                      | .77     |
| **Ischemia time right (min)**| 220 (174,287)| 237.5 (152.5,333.25)|                      | 1.00    |
| **Intraop total no. of blood products**| 11 (9.12)| 12 (11.19.5)|                      | .055    |
| **PGD grade at 72 h (%)**|       |         |                        |         |
| 0 (n = 4)             | 4 (100)| 0 (0)   | 8.437                  | .052    |
| 1 (n = 4)             | 4 (100)| 0 (0)   |                        |         |
| 2 (n = 7)             | 2 (28.57)| 5 (71.43)|                      |         |
| 3 (n = 8)             | 5 (62.5)| 3 (37.5)|                        |         |
| **Hospital stay (d)** | 65 (47.84)| 33 (25.5,85.75)|                      | .175    |

ECMO, extracorporeal membrane oxygenation; intraop, intraoperative; PGD, primary graft dysfunction.
The intraoperative challenges were: 1. as most of the recipients were on ECMO support, LTx was performed on ECMO support, and all of them converted to VA ECMO from VV ECMO preoperatively; and 2. the need for multiple blood products transfusions intraoperatively.

The postoperative challenges were as follows: 1. maintaining tacrolimus levels toward the lower limit of the acceptable range in order to prevent super-added infections from an Indian perspective; 2. aggressive pulmonary rehabilitation required because of significant critical illness neuropathy, 3. tackling a variety of infections (bacterial, viral, and fungal), 4. prolonged tracheostomy care, 5. keeping a low threshold for suspecting rejections and managing them, and 6. delayed wound healing in some recipients.

We had 14 recipients with positive blood cultures, with some recipients among them showing breakthrough infections. This highlights that such phenotypes are probably at risk of multiple infections—post—viral immunosuppression, prolonged courses of steroids and/or Tocilizumab, and comorbidities like diabetes mellitus might contribute to the risk of infections.

In the study published by Bharat et al [9], authors have described their experience of LTx in such phenotypes. Various concerns regarding LTx in patients with SARS-CoV-2 or super-infecting pathogens associated with viral pneumonia in the native lung recurring in the allograft, severe vascular and pleural damage secondary to SARS-CoV-2 infection causing technical barriers to transplant, increasing time that tissues are ischemic leading to worsening of outcomes, severe deconditioning associated with prolonged mechanical ventilation, sedation, and neuromuscular blockade and malnutrition which might complicate recovery after transplant were discussed. The normal functional status of the patients before their SARS-CoV-2—induced pneumonia would reduce the impact of these factors on recovery after LTx. They concluded that some patients with severe COVID-19 develop an irreversible fibrotic lung disease for which transplant is likely their only option for survival.

We would like to raise similar concerns of these patients developing multiple nosocomial complications, neuromuscular deconditioning, and malnutrition due to their complicated medical course, which may be an impediment to transplantation in patients. We found these factors that affected postoperative recovery period for a select few recipients, specifically those with >60 years of age, a body mass index of more than 30, a donor-recipient lung size mismatch leading to anatomic volume reduction in some, prolonged ischemia times, acute kidney injury postoperatively, and so on. More studies are required to analyze the above risk factors in these post-COVID phenotypes going for LTx.

Barbaro et al [10] in their study has reinforced above findings regarding risk factors. Novel findings in this study include determination of independent associations between mortality and risk factors for ECMO-supported patients with COVID-19. Identified risk factors were age, immunocompromised state, chronic respiratory disease, pre-ECMO cardiac arrest, degree of hypoxaemia, presence of acute kidney injury, and use of ECMO for temporary circulatory support (VA ECMO support vs VV ECMO support).

Cypel and Keshavjee [7] have highlighted determinants of LTx. The challenges in selection of candidates for LTx in such situations also has been highlighted by Domjan et al [11]. Extrapolating the above recommendations in patients post-COVID would require some deviations.

We propose that candidacy for LTx in such patients should be decided by the following factors (apart from those mentioned above):

1. Duration of ECMO days with high sequential organ failure assessment scores, specifically from Asian countries where financial constraints and risk of infections on ECMO support could be higher;
2. Preoperative infection status, comprehensively evaluating bacterial, fungal, and viral etiologies beforehand;
3. Assessing neuromuscular deconditioning, using less sedation and neuro-muscular blockades preoperatively;
4. Limitations in pretransplant evaluations specifically for patients on ECMO and ventilatory support referred for LTx;
5. Multiorgan derangement preoperatively on ECMO support while awaiting organ allocation.

Several studies and reviews have been published describing histopathological features in SARS-Cov-2 infected and damaged lungs. Studies by Polak et al [12], Chen et al [13], and Luo et al [14] confirm our histopathological findings of explanted lungs.

Key points elicited for LTx by Yu et al [15], in post-COVID patients are:

1. Confirmed irreversibility of refractory respiratory failure despite maximal medical support;
2. Confirmed positive-turned-negative virology status by performing consecutive nucleic acid tests with samples derived from multiple sites;
3. Confirmed absence of other organ system dysfunction that could contraindicate LTx. LTx was regarded as an urgently needed salvage therapy after full evaluation of the pathologic condition of the patients;
4. Robust rehabilitation procedures and early mobilization for post—COVID-19 patients provided enormous strength to pursue a good quality of life;
5. Head covers with positive pressure are necessary for surgeons, nurses, anesthesiologists, and cardiopulmonary physicians; head covers will help surgeons keep their field of view clear without fogging of eye protectors;
6. Considering the physical demands and challenges for surgeons in full protective clothing, an intraprocedure rotation plan is necessary to guarantee optimal performance during surgery.

Understanding the above key factors is crucial for successful outcomes post-LTx. We propose additional points:

1. Induction immunosuppression should be used in all such recipients as they have higher risk of sensitization.
Strengths and Limitations

Our observations and recommendations have found some similarity in the recent article published by Bharat et al [16]. The authors have elaborated in-detail about criteria for the selection of post-COVID-19 LTx patients. Some criteria, like duration on ECMO support, need for aggressive pulmonary rehabilitation in ICUs preoperation, and optimum nutritional support should be stressed and relevant for recipients from Asian countries.

Reis et al [17], in a Brazilian study of 3 post-COVID LTx recipients, has also shown that LTx is feasible among these complex patients. Survival over the first 30 days was 100%, favoring surgical feasibility. Nevertheless, these were critically ill patients.

Recently, King et al [18] in their review article have highlighted their approach to LTx for COVID-related ARDS or post-COVID fibrosis. Our study also had a similar approach in deciding candidacy for LTx in such patients to find the transplant “sweet spot” as mentioned in article. Centers involved in the above review article don’t represent Asian settings and their inherent challenges. It is imperative to have more work coming from Asian countries like India, China, and Japan to understand critical areas regarding candidacy as 1. ECMO waiting time till listing such phenotype, 2. “waves of infections” while on ECMO and preserving candidacy for LTx, 3. long-term outcomes posttransplant and relation to acute (acute cellular rejection or antibody-mediated rejection) or Chronic Rejections.

Conclusions

Performing LTx in patients post-COVID with ESLD comes with unique challenges. Selecting the right candidates is a challenge in some clinical scenarios. More studies of LTx are required in patients post-COVID with ESLD to understand long-term follow-up, outcomes, and the risk of chronic lung allograft dysfunction.

References

[1] World Health Organization. Coronavirus disease (COVID-19) dashboard. https://covid19.who.int/region/searo/country/in; 2021 [accessed 02.02.22].
[2] Lechowicz K, Droźdzal S, Machaj F, Rosik J, Szotak B, Zegan-Buranska M, et al. COVID-19: the potential treatment of pulmonary fibrosis associated with SARS-CoV-2 infection. J Clin Med 2020;9:1917.
[3] Yuki K, Fujiogi M, Koutsogiannaki S, COVID-19 pathophysiology: a review. Clin Immunol 2020;215:108427.
[4] Guan W, Ni Z, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–20.
[5] Vlachos S, Wong A, Metaxa V, Canestrini S, Lopez Soto C, Periselneris J, et al. Hospital mortality and resource implications of hospitalization with COVID-19 in London, UK: a prospective cohort study. Crit Care Res Pract 2021;2021:8832660.
[6] George PM, Barratt SL, Condiffe R, Desai SR, Devaraj A, Forrest I, et al. Respiratory follow-up of patients with COVID-19 pneumonia. Thorax 2020;75:1009–16.
[7] Cypel M, Keshavjee S. When to consider lung transplantation for COVID-19. Lancet Respir Med 2020;8:944–6.
[8] Lang C, Jakisch P, Hoda MA, Lang G, Staudinger T, Tschernko E, et al. Lung transplantation for COVID-19-associated acute respiratory distress syndrome in a PCR-positive patient. Lancet Respir Med 2020;8:1057–60.
[9] Bharat A, Querrey M, Markov NS, Kim S, Kurihara C, Garza-Castillón R, et al. Lung transplantation for patients with severe COVID-19. Sci Transl Med 2020;12:eabe4282.
[10] Barbaro RP, MacLaren G, Boonstra PS, et al. Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry. Lancet 2020;396:1071–8 [published correction appears in Lancet 2020;396:1070].
[11] Domjan M, Harlander M, Knafelj R, et al. Lung transplantation for end-stage respiratory failure after severe COVID-19: a report of 2 cases. Transplant Proc 2021;53:2495–7.
[12] Polak SB, Van Gool IC, Cohen D, von der Thüsen JH, van Paassen J. A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression. Mod Pathol 2020;33:2128–38.
[13] Chen XJ, Li K, Xu L, Yu YJ, Wu B, He YL, et al. Novel insight from the first lung transplant of a COVID-19 patient. Eur J Clin Invest 2021;51:e13443.
[14] Luo WR, Yu H, Gou JZ, Li XX, Sun Y, Li JX, et al. Histopathologic findings in the explant lungs of a patient with COVID-19 treated with bilateral orthotopic lung transplant. Transplant 2020;104:e329–31.
[15] Chen JY, Qiao K, Liu F, Wu B, Xu X, Jiao GQGH, et al. Lung transplantation as therapeutic option in acute respiratory distress syndrome for coronavirus disease 2019-related pulmonary fibrosis. Chin Med J (Engl) 2020;133:1390–6.

[16] Bharat A, Machuca TN, Querrey M, Kurihara C, Garza-Castillon RJ, Kim S, et al. Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries. Lancet Respir Med 2021;9:487–97.

[17] Reis FP Dos, Fernandes LM, Abdalla LG, Campos SV, Camargo PCLB de, Santos SL Dos, et al. Brazilian initial experience with lung transplantation due to irreversible lung fibrosis post-COVID-19 in a national reference center: a cohort study [e-pub ahead of print]. Sao Paulo Med J doi:10.1590/1516-3180.2021.0842.R1.13102021, accessed December 17, 2021.

[18] King CS, Mannem H, Kukreja J, et al. Lung transplantation for patients with COVID-19. Chest 2022;161:169–78.